IMVT-1402
Graves' Disease
Key Facts
About Roivant Sciences
Founded in 2014, Roivant Sciences operates through a unique 'Vant' model, creating nimble subsidiary companies focused on specific therapeutic areas including Immunovant (autoimmune diseases), Priovant (severe autoimmune conditions), and Pulmovant (pulmonary diseases). The company has demonstrated strong execution with multiple successful Phase 3 trials and commercial launches, including VTAMA for plaque psoriasis. Roivant trades on NASDAQ under ticker ROIV and maintains a broad pipeline of investigational drugs across various therapeutic areas and development phases.
View full company profileAbout Roivant Sciences
Founded in 2014, Roivant Sciences operates through a unique 'Vant' model, creating nimble subsidiary companies focused on specific therapeutic areas including Immunovant (autoimmune diseases), Priovant (severe autoimmune conditions), and Pulmovant (pulmonary diseases). The company has demonstrated strong execution with multiple successful Phase 3 trials and commercial launches, including VTAMA for plaque psoriasis. Roivant trades on NASDAQ under ticker ROIV and maintains a broad pipeline of investigational drugs across various therapeutic areas and development phases.
View full company profileAbout Roivant Sciences
Founded in 2014, Roivant Sciences operates through a unique 'Vant' model, creating nimble subsidiary companies focused on specific therapeutic areas including Immunovant (autoimmune diseases), Priovant (severe autoimmune conditions), and Pulmovant (pulmonary diseases). The company has demonstrated strong execution with multiple successful Phase 3 trials and commercial launches, including VTAMA for plaque psoriasis. Roivant trades on NASDAQ under ticker ROIV and maintains a broad pipeline of investigational drugs across various therapeutic areas and development phases.
View full company profileAbout Roivant Sciences
Founded in 2014, Roivant Sciences operates through a unique 'Vant' model, creating nimble subsidiary companies focused on specific therapeutic areas including Immunovant (autoimmune diseases), Priovant (severe autoimmune conditions), and Pulmovant (pulmonary diseases). The company has demonstrated strong execution with multiple successful Phase 3 trials and commercial launches, including VTAMA for plaque psoriasis. Roivant trades on NASDAQ under ticker ROIV and maintains a broad pipeline of investigational drugs across various therapeutic areas and development phases.
View full company profileAbout Roivant Sciences
Founded in 2014, Roivant Sciences operates through a unique 'Vant' model, creating nimble subsidiary companies focused on specific therapeutic areas including Immunovant (autoimmune diseases), Priovant (severe autoimmune conditions), and Pulmovant (pulmonary diseases). The company has demonstrated strong execution with multiple successful Phase 3 trials and commercial launches, including VTAMA for plaque psoriasis. Roivant trades on NASDAQ under ticker ROIV and maintains a broad pipeline of investigational drugs across various therapeutic areas and development phases.
View full company profileAbout Roivant Sciences
Founded in 2014, Roivant Sciences operates through a unique 'Vant' model, creating nimble subsidiary companies focused on specific therapeutic areas including Immunovant (autoimmune diseases), Priovant (severe autoimmune conditions), and Pulmovant (pulmonary diseases). The company has demonstrated strong execution with multiple successful Phase 3 trials and commercial launches, including VTAMA for plaque psoriasis. Roivant trades on NASDAQ under ticker ROIV and maintains a broad pipeline of investigational drugs across various therapeutic areas and development phases.
View full company profileAbout Immunovant
Immunovant is dedicated to enabling normal lives for people with autoimmune diseases by developing targeted anti-FcRn therapies. The company's lead assets, batoclimab and IMVT-1402, are in clinical development for a range of IgG-mediated conditions, with positive Phase 2b results recently announced for batoclimab. As a subsidiary of Roivant Sciences, Immunovant leverages a patient-focused, innovative approach to address complex autoimmune disease needs.
View full company profile